← back to search

Xiangyou Yu

Shanxi Medical University · CN
🔎 Find collaborators in Cardiology and Cardiovascular Medicine · Genetics →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Cardiology and Cardiovascular Medicine · Genetics
Research interest
Research topics from publications: Circulating expression and clinical significance of LncRNA ANRIL in diabetic kidney disease; Dipeptidyl peptidase 3 is essential for maintaining osteoblastic differentiation under a high-glucose environment by inhibiting apoptosis, oxidative stress and inflammation through the modulation of the Keap1-Nrf2 pathway; Upregulation of BRD7 protects podocytes against high glucose-induced apoptosis by enhancing Nrf2 in a GSK-3β-dependent manner; Patent foramen ovale closure vs. medical therapy alone after cryptogenic stroke in China: A cost-effectiveness analysis; Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers. Representative work: BACKGROUND: Long noncoding RNA ANRIL has been found to be involved in the pathogenesis of diabetic kidney disease (DKD) and is expected to be a new target for prevention of DKD. However, the circulating expression and clinical significance of ANRIL in DKD patients is uncertain. This study aims to explore this issue. METHODS: The study consisted of 20 healthy controls, 22 T2DM patients (normalbuminuria) and 66 DKD patients (grouped as follows: microalbuminuria, n = 23; macroalbuminuria, n = 22 and renal dysfunction, n = 21). The expressions of ANRIL in peripheral whole blood of all participants were measured by RT-qPCR. RESULTS: The expression of ANRIL was significantly up-regulated in DKD pa Background: In 2019, there were 28. 76 million patients with stroke in China, with ~25% of them suffering from cryptogenic stroke (CS). Patent foramen ovale (PFO) is related to CS, and PFO closure can reduce recurrent stroke. To date, no study has investigated the cost-effectiveness of PFO closure vs. medical therapy among such populations in China. Methods: A Markov model with a cycle length of 3 months was established to compare the 30-year cost-effectiveness of PFO closure and medical therapy. The transition probability of recurrent stroke was derived from the RESPECT study, and the costs and utility were obtained from domestic data or studies conducted in China. The primary outcome of th
h-index
citations
0
works
0
NIH funding
primary concept
email

Recent publications

Dipeptidyl peptidase 3 is essential for maintaining osteoblastic differentiation under a high-glucose environment by inhibiting apoptosis, oxidative stress and inflammation through the modulation of the Keap1-Nrf2 pathway
International Immunopharmacology 2023cited by 7position: middledoi
Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers
Clinical Drug Investigation 2023cited by 3position: firstdoi
Circulating expression and clinical significance of LncRNA ANRIL in diabetic kidney disease
Molecular Biology Reports 2022cited by 17position: middledoi
Upregulation of BRD7 protects podocytes against high glucose-induced apoptosis by enhancing Nrf2 in a GSK-3β-dependent manner
Tissue and Cell 2022cited by 4position: firstdoi
Patent foramen ovale closure vs. medical therapy alone after cryptogenic stroke in China: A cost-effectiveness analysis
Frontiers in Public Health 2022cited by 3position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Shenglin He · Shanxi Medical University2 papers (2022–2023)Na Wei · Tianjin University of Traditional Chinese Medicine2 papers (2022–2023)Xuejun Zhang · Capital Medical University2 papers (2022–2023)Fuqiang Liu · Shanxi Medical University2 papers (2022–2023)Meijuan Ma · Shanxi Medical University2 papers (2022–2023)Junkui Wang · Guangdong University of Technology1 papers (2023–2023)Xintian Chen · Shanxi Medical University1 papers (2022–2022)Yan Liang · Jiangsu University1 papers (2022–2022)Qiong Wang · Hunan Children's Hospital1 papers (2022–2022)Xiaoming Wang · Shanxi Medical University1 papers (2022–2022)Jing Li · Shanxi Medical University1 papers (2023–2023)Jing Li · Wannan Medical College1 papers (2022–2022)Xiaofeng Li · Nanchang University1 papers (2023–2023)Xiaofeng Li · Guangzhou Institute of Dermatology1 papers (2022–2022)Zhenjiang Li · Nanchang University1 papers (2022–2022)Wei Zhang · University of Arkansas at Little Rock1 papers (2022–2022)Bo Liu · Children's Hospital of Chongqing Medical University1 papers (2022–2022)Bo Liu · Guangzhou University of Chinese Medicine1 papers (2023–2023)Hao Yan · Jinan University1 papers (2023–2023)Ning Jiang · Brown University1 papers (2022–2022)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Cardiology and Cardiovascular Medicine · Genetics →